Skip to main content

Grand Challenges

Bill & Melinda Gates Foundation

Main menu

  • About
  • Challenges
  • Awarded Grants
  • News
  • Grant Opportunities
  • Search

You are here

  1. Home
  2. Awarded Grants
  3. 2014
  4. 2009

Print link

Print

Awarded Grants

Filter by Initiative

  • Grand Challenges Explorations Apply Grand Challenges Explorations filter (267)
  • Grand Challenges India Apply Grand Challenges India filter (24)
  • Grand Challenges for Development Apply Grand Challenges for Development filter (17)
  • Grand Challenges Apply Grand Challenges filter (1)

Filter by Challenge

Filter by Awarded Year

  • 2019 Apply 2019 filter (121)
  • 2018 Apply 2018 filter (129)
  • 2017 Apply 2017 filter (98)
  • 2016 Apply 2016 filter (162)
  • 2015 Apply 2015 filter (171)
  • (-) Remove 2014 filter 2014 (152)
  • 2013 Apply 2013 filter (184)
  • 2012 Apply 2012 filter (244)
  • 2011 Apply 2011 filter (258)
  • 2010 Apply 2010 filter (142)
  • (-) Remove 2009 filter 2009 (157)
  • 2008 Apply 2008 filter (105)
  • 2006 Apply 2006 filter (1)
  • 2005 Apply 2005 filter (43)

Filter by Country

Grand Challenges is a family of initiatives fostering innovation to solve key global health and development problems. Each initiative is an experiment in the use of challenges to focus innovation on making an impact. Individual challenges address some of the same problems, but from differing perspectives.

Sort by:
Date Awarded
Title (A-Z)
10
25
50
100

Breastmilk shield to prevent HIV transmission

Gadi BorkowCupron, Inc.Richmond, Virginia, United States
Grand Challenges Explorations
HIV Infection
1 May 2009

Gadi Borkow of Cupron, Inc. in the U.S. will study the efficacy of using newly developed copper-oxide based filters that deactivate a wide range of viruses, including HIV-1, as a shield to enable HIV-infected mothers to breastfeed their infants without risking transmission of the virus.

Mortalizing HIV – A Novel Method to Help Eradicate HIV

Reuben HarrisUniversity of MinnesotaMinneapolis, Minnesota, United States
Grand Challenges Explorations
HIV Infection
1 May 2009

A high HIV mutation rate enables escape from powerful immune responses and anti-retroviral drugs. Reuben Harris of the University of Minnesota in the U.S. will test the hypothesis that HIV requires the human APOBEC3G protein to maintain a high mutation rate necessary for HIV survival. Inhibiting this protein may slow the mutation rate and make the virus more susceptible to immune responses.

Using Materials Science to Stop HIV Sexual Transmission

Patrick KiserUniversity of UtahSalt Lake City, Utah, United States
Grand Challenges Explorations
HIV Infection
1 May 2009

Patrick Kiser of the University of Utah in the U.S. will design a vaginal gel that blocks HIV by becoming impermeable in response to the pH change induced by the presence of semen, and includes a polymer engineered to bind to HIV surface proteins to halt viral transport to susceptible tissues and HIV target cells. In this project's Phase I research, Kiser and his team engineered a synthetic polymer that has many of the properties of mucus, and demonstrated that the polymers slow or stops the movement of cells in the presence of semen. In Phase II, Kiser will focus on developing a pericoital contraceptive gel that will prevent the movement of spermatozoa into the uterus.

Zinc Finger Nucleases For in vivo Treatment of HIV Infection

Philip GregorySangamo BioSciences IncRichmond, California, United States
Grand Challenges Explorations
HIV Infection
1 May 2009

People born with a genetic mutation in their CCR5 gene are naturally resistant to HIV infection. Philip Gregory of Sangamo BioSciences, Inc. in the U.S. will use zinc finger nuclease technology to specifically disrupt the CCR5 gene as a new strategy to make people resistant to HIV.

A Non-Pathogenic Chimeric THLV-1/HIV-1 Viral Genome as a Model to Study Superinfection Restriction

Kuan-Teh JeangNational Institutes of HealthBethesda, Maryland, United States
Grand Challenges Explorations
HIV Infection
1 May 2009

Kuan-Teh Jeang of the National Institutes of Health in the U.S. will investigate whether cells infected by one virus become resistant to infection from other viruses, and if this viral interference can confer protection against HIV. The team will develop an attenuated virus to test whether over-expression of viral envelope proteins within cells can confer resistance to further HIV infection.

A Small Molecule That Blocks Male-to-Female Sexual Transmission of HIV

David EisenbergUniversity of California, Los AngelesLos Angeles, California, United States
Grand Challenges Explorations
HIV Infection
1 May 2009

Recent evidence suggests that HIV infection may be drastically enhanced when a specific protein found in human semen is present in fibril form. David Eisenberg of UCLA in the U.S. will design and test a small peptide that can effectively block formation of fibrils on this protein. If successful, the therapy could be administered via spray or liquid drops to inhibit transmission of HIV.

A Self-Adjuvanting Vaccine for ST-ETEC

Roy Robins-BrowneUniversity of MelbourneMelbourne, Victoria, Australia
Grand Challenges Explorations
Vaccines
1 May 2009

Enterotoxigenic E. coli (ETEC) is the leading cause of diarrhea in the developing world. Roy Robins-Browne, of the University of Melbourne, in Australia will evaluate the effectiveness of a prototype vaccine that combines enterotoxin of E. coli (which lacks immunogenicity by itself) with another epitope to attract helper T cells and a lipid adjuvant to ensure delivery of the antigen directly into the cell.

Development of a Synthetic Anti-Toxic Vaccine for Malaria

Louis SchofieldThe Walter and Eliza Hall Institute of Medical ResearchVictoria, Victoria, Australia
Grand Challenges Explorations
Vaccines
1 May 2009

Louis Schofield of The Walter and Eliza Hall Institute in Australia will develop a synthetic saccharide-conjugated vaccine that would provide immunity against GPI, a toxin produced by the malaria parasite that is a major determinant in the severity and fatality of the disease. This project's Phase I research demonstrated preclinical safety and efficacy of a synthetic anti-toxin vaccine for malaria, showing that the oligosaccharide target was conserved across all malaria species and life stages. In Phase II, Schofield is extending the preclinical evaluation of efficacy of this candidate vaccine against other species and life stages.

Liposomal Dendiritc-Cell (DC)-Targeted Vaccines for TB

Ines AtmosukartoLipotek Pty LtdCanberra, Australian Capital Territory, Australia
Grand Challenges Explorations
Vaccines
1 May 2009

Ines Atmosukarto of Lipotek Pty Ltd. in Australia proposes to develop a novel TB vaccine utilizing synthetic “nano-sacs” called liposomes that carry TB antigens and are anchored with a self-adjuvanting protein that binds to and stimulates dendritic cells.

An Altruistic Vaccine for Mosquito Transmitted Pathogens

Paul YoungUniversity of QueenslandBrisbane, Queensland, Australia
Grand Challenges Explorations
Infectious Diseases
1 May 2009

Mosquito transmitted pathogens such as dengue and malaria are a significant disease burden on the world's population. Paul Young of the University of Queensland in Australia aims to develop a novel vaccine approach that is based on blocking mosquito transmission of these disease agents rather than inducing pathogen- specific immunity.

Pages

  • Currently on page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • …
  • Next page
  • Last page
Sort by:
Date Awarded
Title (A-Z)
10
25
50
100

Contact us

Contact us

  • General Inquiries
  • Media Inquiries

Footer - Receive Updates

Receive updates

  • Sign up for email updates

Footer

  • Privacy Policy and Terms of Use
© 2003-2019. Grand Challenges. All Rights Reserved.

PLEASE REVIEW OUR UPDATED PRIVACY & COOKIES NOTICE

This site uses cookies and similar technologies to store information on your computer or device. By continuing to use this site, you agree to the placement of these cookies and similar technologies. Read our updated Privacy & Cookies Notice to learn more.